60 results about "Propynyl" patented technology

The invention relates to the field of batteries, and relates to a battery, the battery comprises an electrolyte and a negative pole piece, the electrolyte comprises a first additive and a second additive, and the first additive has a structure as shown in a formula 1; the second additive comprises at least one of tripropargyl phosphate, propyl phosphate bis (2-propynyl) ester and ethyl phosphate bis (2-propynyl) ester; the negative pole piece comprises a negative active material, and the negative active material comprises a silicon element. The battery containing the additive is high in interface flatness and good in cycle performance. # imgabs0 #

The invention belongs to the technical field of biological medicines, and particularly relates to a pyruvate preparation for treating non-small cell lung cancer and a preparation method of the pyruvate preparation. The pyruvate preparation is prepared from the following components in parts by weight: 0.03 to 0.05 part of sodium pyruvate, 0.01 to 0.03 part of synergist and 100 parts of water for injection. The preparation method of the synergist comprises the following steps: adding sodium pyruvate into a 3, 4-diaminophenol solution for reaction to obtain an intermediate 1; reacting the intermediate 1 with 4-chloro-1, 2-phenylenediamine to obtain an intermediate 2; reacting p-hydroxybenzaldehyde with propynyl chloride to obtain an intermediate 3; reacting the intermediate 3 with 1-azido-4-chlorobenzene to obtain an intermediate 4; and reacting the intermediate 2 with the intermediate 4 to obtain the synergist. Experimental results show that the synergistic agent and the sodium pyruvate are matched to achieve an excellent anti-tumor effect, and particularly, the selectivity of inhibition on non-small cell lung cancer tumors is shown.

A cleansing wet wipe in which a base paper sheet is impregnated with a chemical liquid. The chemical liquid contains at least iodopropynyl butylcarbamate, polyamino-propyl biguanide, benzalkonium chloride, and cetylpyridinium chloride; and the content value for the iodopropynyl butylcarbamate in the chemical liquid is 0.005-0.02 mass % inclusive. The chemical liquid is adjusted to be acidic.

The invention discloses a preparation method, an intermediate and application of menochromone. The preparation method comprises the following steps: reacting 4-bromopyrrole-2-carboxylic acid with propargylamine to generate 4-bromo-N-propynyl pyrrole-2-formamide; the preparation method comprises the following steps: reacting 4-bromo-N-propinyl pyrrole-2-formamide with pinacol borane to generate a mixture; reacting the mixture with 2-(t-butyloxycarboryl amino)-5-iodo-1H-imidazole to generate (E)-(5-(3-(4-bromo-1H-pyrrole-2-formamido) prop-1-ene-1-yl)-1H-imidazole-2-yl) tert-butyl carbamate, and reacting the (E)-(5-(3-(4-bromo-1H-pyrrole-2-formamido) prop-1-ene-1-yl)-1H-imidazole-2-yl) tert-butyl carbamate with the tert-butyl carbamate; and reacting the (E)-(5-(3-(4-bromo-1H-pyrrole-2-formamido) prop-1-ene-1-yl)-1H-imidazole-2-yl) tert-butyl carbamate with a dioxane hydrochloride solution, so as to generate the menochromone. The invention provides a preparation method of menosin, which is short in synthetic route, simple and convenient to operate, high in product yield and suitable for industrial production.

The invention discloses an icaritin derivative, a composition and application, the structural formula of the icaritin derivative is as follows: in the structural formula, R1 is independently selected from hydrogen, hydroxyl and C1-C3 alkoxy; r2 is independently selected from hydrogen, an isopentenyl group, an isoamyl group and a Mannich base; r3 is independently selected from hydrogen, hydroxyl or OR3 ', R3 'is selected from rhamnosyl, rhamnose-(2-> 1)-glucosyl, rhamnose-(3-> 1)-glucosyl, propynyl and triazole groups substituted by alcoholic hydroxyl, benzyl and glycosyl; r4 is independently selected from a hydroxyl group or OR4 ', and R4' is selected from a propynyl group, a glucosyl group, and an alcoholic hydroxyl group, a benzyl group and a glycosyl substituted triazole group; r5 is independently selected from hydrogen, isopentenyl and Mannich base; mannich base is selected from N (CH3) 2 and N (CH2CH3) 2, R6 is independently selected from hydroxyl and OR6 ', and R6' is selected from hydrogen, rhamnosyl, rhamnose-(2-> 1)-xylosyl and rhamnose-(2-> 1)-rhamnosyl.The icaritin derivative provides a new direction for treatment of sarcopenia.

The present invention relates to a composition containing (a) a guanidine and / or an unsubstituted guanidine salt, and (b) at least one further component selected from the group consisting of 5-chloro-2-methyl-4-isothiazolin-3-one, 2-methyl-4-isothiazolin-3-one, 1, 2-benzisothiazolin-3-one, N-butyl-1, 2-benzisothiazolin-3-one, N-methyl-1, 2-benzisothiazolin-3-one, N-methyl-1, 2-benzisothiazolin-3-one, N-methyl-1, 2-benzisothiazolin-3-one, N-methyl-1, 2-benzisothiazolin-3-one, N-methyl-1, 2-benzisothiazolin-3-one, N-methyl-1, 2-benzisothiazolin-3-one, N-methyl-1, 2-benzisothiazolin-3-one, N-methyl-1, the cleaning agent is prepared from 2-benzisothiazolin-3-one, octyl isothiazolinone, bronopol, dibromo-nitrilopropionamide, dibromo-dicyanobutane, butyl carbamic acid iodopropynyl ester, aminomethyl propanol, aminoethyl propylene glycol, monoethanolamine, ethylhexylglycerin, hexylglycerin, 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-heptanediol, 1, 2-octylene glycol, phenoxy ethanol and phenethyl alcohol. The cleaning agent is prepared from phenyl propanol, benzyl alcohol, isopropanol, ethylenediamine tetraacetic acid, (1-hydroxyethylidene) diphosphonic acid, 2-mercaptopyridine sodium oxide, 2-mercaptopyridine zinc oxide, o-phenylphenol, sorbic acid, benzoic acid, salicylic acid, lactic acid, citric acid and zinc. The invention also relates to an industrial product containing components (a) and (b), and to the use of said composition for the preservation of containers and for the preservation of industrial products. The invention also relates to the use of (a) a guanidine and / or an unsubstituted guanidine salt for improving the antimicrobial efficacy of one or more compounds selected from the group (b) described above.

The invention discloses a nickel pre-plating additive suitable for a high area and an electroplating method. The invention discloses a cleaning agent, which comprises the following five main functional additives: 10-20 wt% of a surfactant, 10-20 wt% of a brightening agent, 4-8 wt% of a leveling agent, 10-15 wt% of a softening agent, 8-12 wt% of a surface cleaning agent, 1-3 wt% of a wetting agent and the balance of five main functional additives. Wherein the brightener mainly comprises one or a mixture of more of pyridinium propyl sulfobetaine (PPS), a sodium allysulfonate aqueous solution (ALS), trichloroacetaldehyde hydrate (TCA), 1, 4-butynediol (BOZ), pyridinium hydroxy propyl sulfobetaine (PPS-OH) and butynediol ethyl oxide (BEO). The leveling machine mainly comprises one or a mixture of more of pyridinium sulfobetaine (PPS), propargyl alcohol ethyl oxide (PME), propargyl alcohol propoxy compound (PAP), butynediol propoxy compound (BMP), N, N-diethyl propargyl amine formate (PABS) and pyridinium hydroxy propyl sulfobetaine (PPS-OH). The softening agent mainly comprises one or a mixture of more of a sodium allysulfonate aqueous solution (ALS), sodium allysulfonate (SAS), N, N-diethyl propynylamine (DEP) and propinyl-3-sulfopropyl ether sodium salt (POPS). The surface cleaning agent mainly comprises one or a mixture of more of sodium gluconate, sodium benzoate, sodium salicylate, sodium acetate, sodium hypophosphite and 2, 5-dimethyl-3-hexyne-2, 5-diol (HD-M). The wetting agent mainly comprises one or a mixture of more of 2-ethylhexyl sodium sulfate (TC-EHS), sodium dihexyl sulfosuccinate and sodium mono (2-ethylhexyl) sulfate. The corresponding substances are classified according to the characteristics of the additive, and the dispersing capacity of the plating solution is remarkably enhanced by utilizing mutual synergism and combined action of different substances and matching with the formula of the Watt plating solution. Meanwhile, matching is carried out according to the characteristics of the nickel pre-plated steel strip, and the nickel pre-plated steel strip has the advantages of being suitable for a high-current-density interval, adjustable in coating glossiness, good in coating ductility, good in compactness, few in pinhole, few in blue point and the like.

Described herein are fabric softening compositions comprising a quaternary ammonium compound (e.g., an esterquat); a cationic polyquaternium polymer (e g., polyquaternium-7); a preservative system which comprises an organic acid (e.g., lactic acid or phosphonic acid); and 3-iodo-2-propynyl butylcarbamate (IPBC) or Dodecylguanidine Hydrochloride (DGH); and a phosphonic chelating agent (e.g., etidronic acid). Methods of making and using the fabric softening compositions are also described herein.

The invention relates to blends from iodopropargyl compound-containing and nitrogen-containing polymers with at least two beta aminoamine functions, to the preparation of these blends and to the use of these blends for the protection of technical materials from destruction by microorganisms, and to the technical materials finished with these blends

The invention relates to compounds and pharmaceutically acceptable salts thereof, and to their medical use. Exemplary medical uses are the prevention and treatment of a bacterial infection, for example, a mycobacterial infection, such as a Mycobacterium tuberculosis infection, e.g., in a respiratory system and / or extrapulmonic. The invention further relates to a use of such compounds, pharmaceutically acceptable salts thereof or prodrugs of the compounds as chemotherapeutic agents. Also, the invention relates to a use of such compounds, pharmaceutically acceptable salts thereof or prodrugs of the compounds for inhibiting mycobacterial type VII secretion.The compounds have the following formulawhereinQ and X are, respectively, CH and C, CR2 and C, CH and N, CR2 and N, or N and C;R1 is hydrogen, halide or optionally substituted linear or branched alkoxy having 1 or 2 carbon atoms;R2 is independently selected from hydrogen, halide or optionally substituted linear or branched alkoxy having 1 or 2 carbon atoms, andR3 is optionally substituted linear or branched alkoxy having 1-6 carbon atoms, haloalkyl having 1-6 carbon atoms, n-propyl, 2-propenyl, 2-propynyl, or n-pentyl,or a pharmaceutically acceptable salt of the compound, for use in the prevention or treatment of a bacterial infection.

The application discloses a polyarylbutene and a preparation method and application thereof. The polyarylbutene is obtained by polymerizing a multi-propargyl compound and a methylene compound in an organic solvent under the protection of inert gas. The method has mild conditions, the polymerized monomers are simple and easy to obtain, the polymer has high yield, high molecular weight, high atomic economy, and excellent regioselectivity and stereoselectivity. The polyarylbutene has excellent processability and high thermal stability, high refractive index, metal ion fluorescence quenching, and cell imaging, and can be applied to the fields of optics, detection, biology, medicine and environment.

Battery, including: an electrolyte comprising a first additive and a second additive, wherein the first additive has a structure represented by formula 1 and wherein the second additive comprises at least one of tripropargyl phosphate, propyl bis(2-propynyl) phosphate or ethyl bis(2-propynyl) phosphate; and a negative electrode plate comprising a negative electrode active material, wherein the negative electrode active material comprises the element silicon,

The present disclosure relates to the field of chemistry and medicine, and more particularly to a process for the preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl]-5-methyl-N-propyl-2-alkynyl-1, 3-thiazol-2-amine (Compound 1), pharmaceutically acceptable salts and crystalline forms thereof, as well as methods for the preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl]-5-methyl-N-propyl-2-alkynyl-1, 3-thiazol-2-amine (Compound 1). Methods for the treatment of congenital adrenal hyperplasia (CAH).

The invention discloses a novel chiral covalent organic framework mimic enzyme catalyst and its preparation method and application, the preparation method comprises the following steps: 1,3,5-tris (4-aminophenyl) benzene, 2,5-bis (prop-2-yn-1-yloxy) terephthalaldehyde and dialdehyde monomers with different functional groups are dissolved in an organic solvent, an acetic acid aqueous solution is added, and the reaction is carried out at 80-120 DEG C for 2-4 days to obtain a three-component covalent organic framework material with different properties, and then a small molecule catalyst, i.e., a proline derivative, is fixed in the framework by a click reaction, and then washed, dried and deprotected to obtain a chiral covalent organic framework catalyst. The chiral covalent organic framework material prepared by the present invention is used as a heterogeneous catalyst for asymmetric aldol condensation reaction in a green solvent aqueous phase, showing good catalytic effect and chiral selectivity. After the reaction, the catalyst can be separated and recovered by simple centrifugation or filtration, effectively reducing environmental pollution, while reducing costs, and having good application prospects.

Examples of a biocide composition include an activated halogen compound selected from the group consisting of 2,2-dibromo-3-nitrlopropionamide; 2-bromo-2-nitropropane-1,3-diol; and 1,2-dibromo-2,4-dicyanobutane; benzisothiazolin-3-one; a pyridine-N-oxide selected from the group consisting of zinc pyrithione and sodium pyrithione; and a carbamate derivative selected from the group consisting of 3-iodo-2-propynyl butyl carbamate; zinc bis(dimethyldithiocarbamate); and bis(dimethyl carbamoyl) disulfide.

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders that result in enzyme deficiencies that alter the production of adrenal steroids, due to 21-hydroxylase deficiency (a condition in which little or no cortisol biosynthesis occurs). A method is provided for administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-propa-2-inyl-1,3-thiazole-2-amine, or a pharmaceutically acceptable salt thereof, to adult subjects with congenital adrenal hyperplasia.

Three kinds of functionalized three-dimensional covalent organic framework materials, preparation method and application thereof in gas adsorption and separation belong to the technical field of porous organic framework material preparation.The three kinds of functionalized three-dimensional covalent organic framework materials TAM-DETP, TAM-DMTA and TAM-BPTA with ethoxyl, methyl and prop-2-yn-1-yloxy in the skeleton are prepared by Schiff base reaction with 2,5-diethoxyl terephthaldehyde, 2,5-dimethyl terephthaldehyde, 2,5-bis(prop-2-yn-1-yloxy) terephthaldehyde and tetra(4-aminophenyl) methane as raw materials under the catalysis of acetic acid, which are long-range ordered crystalline porous materials.The separation ratio of carbon dioxide / methane of TAM-BPTA is 23 at 273K and 100kPa; the separation ratio of carbon dioxide / methane of TAM-BPTA is 44 at 298K and 100kPa.

Provided are methods related to the treatment of congenital adrenal hyperplasia in a subject in need thereof, the methods comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl]-5-methyl-N-propyl-2-alkynyl-1, 3-thiazol-2-amine (Formula I), or a pharmaceutically acceptable salt thereof, and methods of treating congenital adrenal hyperplasia in a subject in need thereof, the methods comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl]-5-methyl-N-propyl-2-alkynyl-1, 3-thiazol-2-amine. Further provided are pharmaceutical formulations and solid forms of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl]-5-methyl-N-propyl-2-alkynyl-1, 3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, and their use in the treatment of congenital adrenal hyperplasia (CAH), as well as pharmaceutical formulations and solid forms of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl]-5-methyl-N-propyl-2-alkynyl-1, 3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof.

The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.

This invention discloses a method for preparing monohydroxymethylcyclopropane nucleoside analogs. The method includes: sequentially adding a vinyl nucleobase derivative and a propynyl thioacetal compound to a mixture of a gold-nitrogen heterocyclic carbene catalyst and a silver salt under inert gas protection. After reaction, a highly stereospecific and selective disulfide vinylcyclopropane nucleoside analog is obtained. Following hydrodesulfurization, a vinylcyclopropane nucleoside analog is obtained. Further oxidation, reduction, or deprotection in three steps yields the monohydroxymethylcyclopropane nucleoside analog. This invention provides a concise new route for the synthesis of vinylcyclopropane nucleoside and monohydroxymethylcyclopropane nucleoside analogs, with mild reaction conditions, overcoming the potential explosiveness and lengthy synthetic routes of traditional methods. The raw materials are readily available, and the product can be converted into various other useful potential bioactive molecules, demonstrating strong practicality.

This application provides a method for preparing methylcarboxylic acid-2-propynyl ester, comprising the following steps: (1) mixing dimethyl carbonate and propargyl alcohol, adding a first alkaline catalyst, stirring and heating to a temperature of 90-105°C, and distilling out methanol by reactive distillation to obtain a first component; (2) performing solid-liquid separation on the first component to obtain a first liquid, and performing vacuum distillation on the first liquid to remove propargyl alcohol and dimethyl carbonate to obtain methylcarboxylic acid-2-propynyl ester and residue; (3) performing vacuum distillation on the residue, replenishing dimethyl carbonate and the second alkaline catalyst with the distillate for reaction, and reusing the reaction liquid in step (2). This application uses the transesterification reaction of propargyl alcohol and dimethyl carbonate to synthesize methylcarboxylic acid-2-propynyl ester, which has high safety, low overall reaction temperature, fewer by-products and waste, and high yield.

The invention relates to the technical field of organic synthesis, in particular to a green synthesis process of flumioxazin, which comprises the following steps: S1) taking 6-amino-7-fluoro-4-propinyl-1, 4-benzoxazine-3 (4H) ketone and 3, 4, 5, 6-tetrahydrophthalic anhydride as raw materials, carrying out first reaction at-20 to 50 DEG C, and filtering to obtain a first solid; and S2) carrying out a second reaction on the first solid at 80-120 DEG C to obtain the flumioxazin. According to the method, the temperature of the first reaction is controlled to generate the first solid as the intermediate, the obtained first solid is filtered to effectively remove the impurities by utilizing the characteristic that the intermediates and the impurities have different solubilities in different solvents, and then the second reaction is performed to obtain the flumioxazin, so that the subsequent product does not need recrystallization / pulping operation, and the yield is high. The target product almost has no separation loss. The method provided by the invention is mild in reaction condition, simple in post-treatment and high in product yield and purity.

The invention discloses a preparation method of an oxadiargyl sustained-release microcapsule suspending agent, which is characterized in that monodispersed silicon dioxide nanoparticles are used as a carrier, and a capsule wall is formed through the synergistic effect of chitosan and sodium alginate, so that directional adsorption and controllable release of oxadiargyl are realized. According to the oxadiargyl sustained-release microcapsule suspending agent disclosed by the invention, the action time of a drug on a target is prolonged through controlled release of the drug, the suspending agent is continuously effective in the growth cycle of crops, the number of times of applying the drug to the crops is reduced, the damage to the crops is reduced, the pollution to the environment is reduced, and the labor is saved. Meanwhile, due to the protection effect of the microcapsules, the storage stability of the preparation is improved.

The present disclosure relates generally to the treatment of adrenal dysfunction (such as congenital adrenal hyperplasia) with a combination of 2‑thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-2-propyn-1-yl (crinecerfont) and certain pharmaceutical compositions of hydrocortisone (such as a delayed release oral pharmaceutical composition of hydrocortisone).

The application relates to the technical field of lithium ion batteries, in particular to an electrolyte and a battery. The electrolyte comprises an additive, a lithium salt, an organic solvent and an ionic liquid, wherein the additive comprises at least one of compounds with the structures shown in the following formula; in the formula, R1 is selected from any one of a methyl group, a propyl group, an ethyl group, an allyl group, a vinyl group, a propenyl group, an allyl group, an isopropenyl group, an ethynyl group, a propargyl group, a propynyl group, a 2-propenyl group, a 2-propynyl group, an isopropyl group, an ethynyl group and a tert-butyl group. The electrolyte of the application avoids capacity loss caused by three-step phase transition conversion of a traditional liquid electrolyte, can effectively prevent dissolution of polysulfides, and improves the fire-retardant effect, ionic conductivity and thermal chemical stability of the electrolyte.

The utility model discloses a gas purification device for preparation based on propynyl, which comprises a purification box, a purification structure, a feeding pipe, a feeding valve, an exhaust pipe, an exhaust valve and a spraying box, and relates to the technical field of gas purification, the gas purification device integrates multiple innovative designs and shows obvious advantages; firstly, according to the unique purification structure, through the principle of a stirring driver and a magnetic transmission, automatic rotation of a rotating circular ring, an inserting and sleeving shaft pipe and a cobweb exhaust pipe is achieved, and through the design, the contact area of gas and a purification assembly is increased, and the purification efficiency is greatly improved; meanwhile, due to the ingenious installation of the trumpet-shaped gathering piece, the gas can be gathered and guided to the purification assembly, the one-way Tesla valve effect is further formed, one-way drainage of the gas is ensured, and the purification effect is further improved.

The present disclosure relates to the adipate and malonate salts of 5-((1 R,4R)-2-oxa-5-azabicyclo [2.2.1]heptan-5-yl)-N-(3-( difluoromethyl)-1-((1r,4R)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1 Hbenzo[d]imidazol-4-yl)prop-2-yn-1 -yl)oxy) piperidin-1-yl)methyl)cyclohexyl)-1 H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamid, to their crystalline forms, to their preparation and to their therapeutic use.

The invention discloses a synthesis method of (9S, 10R)-9, 10-epoxy-10-undecyl-3, 6-diyne-1-alcohol, which comprises the following steps: taking (Z)-1-bromotetradecene and 2-(2-propinyl-1-yloxy) tetrahydro-2H-pyran as raw materials, removing pyran by using a catalyst, and converting alcohol into halogenated hydrocarbon under mild conditions; (9S, 10R)-9, 10-epoxy-10-undecyl-3, 6-diyne-1-alcohol is obtained by taking 9, 10-epoxy-10-undecyl-3, 6-diyne-1-alcohol as a raw material, performing substitution with alkynol at room temperature and performing epoxidation under the catalysis of an epoxidation catalyst. The method is simple to operate, low in production cost, mild in synthesis condition and high in yield.

The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.

The present invention discloses a galangin derivative, a preparation method thereof, a pharmaceutical composition and an application. The chemical name of the galangin derivative is (S)-7-propynyl-5-methoxydihydroflavone. The preparation method is as follows: Weigh galangin powder, add 3-bromopropyne, potassium carbonate and dichloromethane, stir at room temperature, add water after 12 h, extract with ethyl acetate, wash the obtained ethyl acetate extract successively with double distilled water and saturated brine, dry with anhydrous sodium sulfate, and then separate by silica gel column, and elute with petroleum ether-ethyl acetate solution gradient to obtain. The galangin derivative can be used in an anti-tumor pharmaceutical composition and has an anti-tumor effect. The galangin derivative of the present invention introduces an alkynyl group into the galangin structure, so that it achieves a better anti-tumor effect and has obvious anti-tumor activity against both liver cancer and lung cancer. Moreover, the preparation method is simple, the yield is high, the cost is low, and the preparation process is non-toxic and harmless, which is suitable for industrial production.